Results 181 to 190 of about 18,735,403 (324)

The enigma of the vertical dimension

open access: yes, 2000
http://babel.hathitrust.org/cgi/pt?id=mdp.39015050714057;view=2up;ui=fullscreen#page/n0/mode ...
Symposium on Craniofacial Growth
core  

Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer

open access: yesMolecular Oncology, EarlyView.
Cancer cells' high translational demand creates opportunities to therapeutically target ribosome function. Ribosome stalling and collisions activate ZAKα and the ribotoxic stress response (RSR), which can trigger rapid, p53‐independent apoptosis in cancer.
Anastassiya Kim   +7 more
wiley   +1 more source

Orthodontics in an aging society

open access: yes, 1989
http://babel.hathitrust.org/cgi/pt?id=mdp.39015013799666;view=2up;ui=fullscreen#page/n0/mode ...
Symposium on Craniofacial Growth
core  

The VHL tumor suppressor at the crossroad of protein folding, aggregation, and cancer

open access: yesMolecular Oncology, EarlyView.
Mutations, environmental stress, and chaperone dysfunction can destabilize pVHL, promoting its conversion from the native folded state into amyloid‐like assemblies. This transition may contribute to protein storage, cell dormancy, survival, and drug resistance.
Lara Abad   +2 more
wiley   +1 more source

Gut microbiota alterations in patients with non‐small‐cell lung cancer undergoing chemoradiotherapy

open access: yesMolecular Oncology, EarlyView.
We investigated the impact of concurrent chemoradiotherapy (CRT) on the gut microbiota in patients with locally advanced non‐small‐cell lung cancer. Overall gut microbiota composition remained largely stable throughout CRT while antibiotic exposure may influence microbial diversity.
Hanne Marte Nymoen   +19 more
wiley   +1 more source

Predictive and prognostic biomarkers of Bacillus Calmette‐Guérin therapy failure in bladder cancer patients: A systematic review

open access: yesMolecular Oncology, EarlyView.
High‐risk bladder cancer is typically treated with Bacillus Calmette‐Guérin (BCG), but 30–40% of patients relapse. No FDA‐ or CE‐approved biomarkers currently predict or prognosticate BCG failure. We systematically reviewed the literature and identified 72 eligible studies, revealing several promising biomarkers associated with BCG treatment response ...
Rui Ribeiro‐Pereira   +7 more
wiley   +1 more source

Bridging tumor growth dynamics and survival in preclinical oncology drug development - a Tumor Growth Inhibition and Time-to-Event (TGI-TTE) modeling framework. [PDF]

open access: yesCancer Chemother Pharmacol
Niloy KK   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy